CytoMed Therapeutics LTD Sample Contracts

UNDERWRITING AGREEMENT between CYTOMED THERAPEUTICS LIMITED and THE BENCHMARK COMPANY, LLC as Representative of the Several Underwriters CYTOMED THERAPEUTICS LIMITED
Underwriting Agreement • March 28th, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations • New York

The undersigned, CytoMed Therapeutics Limited, a public company limited by shares pursuant to the provisions of the Singapore Companies Act formed under the laws of the Republic of Singapore (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of CytoMed Therapeutics Limited, the “Company”), hereby confirms its agreement (this “Agreement”) with The Benchmark Company, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

Sample 1Sample 2Sample 3See All (1k)
AutoNDA by SimpleDocs
UNDERWRITING AGREEMENT between CYTOMED THERAPEUTICS LIMITED and THE BENCHMARK COMPANY, LLC as Representative of the Several Underwriters CYTOMED THERAPEUTICS LIMITED
Underwriting Agreement • April 18th, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations • New York

The undersigned, CytoMed Therapeutics Limited, a public company limited by shares pursuant to the provisions of the Singapore Companies Act formed under the laws of the Republic of Singapore (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of CytoMed Therapeutics Limited, the “Company”), hereby confirms its agreement (this “Agreement”) with The Benchmark Company, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

Sample 1Sample 2Sample 3See All (9)
Contract
Convertible Loan Agreement • February 1st, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential

Sample 1Sample 2Sample 3See All (4)
Form of Representative’s Warrant Agreement
Representative’s Warrant Agreement • April 18th, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations

THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ____, 2023 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the commencement date of sales in the Offering (the “Termination Date”) but not thereafter, to subscribe for and purchase from CytoMed Therapeutics Limited, a public company limited by shares pursuant to the provisions of the Singapore Companies Act formed under the laws of the Republic of Singapore (the “Company”), up to ______ Ordinary Shares, no par value per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defi

Sample 1Sample 2Sample 3See All (4)
SERVICE AGREEMENT
Service Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

This Service Agreement (“Agreement”) is made of and entered into on 08th September 2021 between CytoMed Therapeutics (Malaysia) Sdn. Bhd. (“Company”) and Choo Chee Kong (“Service Provider”).

Sample 1Sample 2Sample 3
Contract
Put Option Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Sample 1Sample 2Sample 3
Contract
License Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Sample 1Sample 2Sample 3
Contract
Shareholders Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Sample 1Sample 2Sample 3
Contract
Licence Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Sample 1Sample 2Sample 3
Contract
License Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Sample 1Sample 2Sample 3
Contract
Supplemental Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Sample 1Sample 2
Contract
Subscription Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Sample 1Sample 2
CYTOMED THERAPEUTICS PTE LTD
Convertible Loan Agreement • February 1st, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations
Sample 1
THIS AGREEMENT IS MADE THIS 6TH DAY F MAY 2024 BETWEEN CELLSAFE INTERNATIONAL SDN BHD (IN LIQUIDATION) (REGISTRATION NO. 200601028503 (748259-P) (“VENDOR”) AND IPSC DEPOSITORY SDN BHD (REGISTRATION NO. 201901022718 (1332047-T)) (“PURCHASER”)
Master Agreement • October 3rd, 2024 • CytoMed Therapeutics LTD • Pharmaceutical preparations
Sample 1
ADDENDUM TO LICENCE AGREEMENT
License Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

ACCELERATE TECHNOLOGIES PTE LTD, f.k.a.EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1995053187D), a company incorporated in Singapore and having its place of business at 1 Fusionopolis Way, #19-00 Connexis North, Singapore 138632 (hereinafter referred to as “A*ccelerate”) ; and

Sample 1
CONVERTIBLE LOAN AGREEMENT — Supplemental Agreement No. 1
Convertible Loan Agreement • February 1st, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations
Sample 1
dated ___________ (THE SUBSCRIBER) AND CYTOMED THERAPEUTICS PTE LTD (THE COMPANY) subscription agreement Relating to shares in the capital of CYTOMED THERAPEUTICS PTE LTD
Subscription Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Sample 1
Contract
Clinical Study Agreement • March 28th, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential

Sample 1
THIS AGREEMENT is made on the day of 2023
Employment Agreement • February 1st, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations

NOW IT IS AGREED that the Company will appoint the Executive and the Executive will serve the Company as an executive of the Company on the terms and conditions set out as follows from the Commencement Date (as defined below), notwithstanding the date of this Agreement:

Sample 1
ADDENDUM TO LICENCE AGREEMENT
Licensing Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

ACCELERATE TECHNOLOGIES PTE LTD, f.k.a.EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1995053187D), a company incorporated in Singapore and having its place of business at 1 Fusionopolis Way, #19-00 Connexis North, Singapore 138632 (hereinafter referred to as “A*ccelerate”) ; and

Sample 1
Contract
Convertible Loan Agreement • February 1st, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential

Sample 1
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!